1
|
Georgieva AM, Guo X, Bartkuhn M, Günther S, Künne C, Smolka C, Atzberger A, Gärtner U, Mamchaoui K, Bober E, Zhou Y, Yuan X, Braun T. Inactivation of Sirt6 ameliorates muscular dystrophy in mdx mice by releasing suppression of utrophin expression. Nat Commun 2022; 13:4184. [PMID: 35859073 PMCID: PMC9300598 DOI: 10.1038/s41467-022-31798-z] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2021] [Accepted: 06/30/2022] [Indexed: 11/18/2022] Open
Abstract
The NAD+-dependent SIRT1-7 family of protein deacetylases plays a vital role in various molecular pathways related to stress response, DNA repair, aging and metabolism. Increased activity of individual sirtuins often exerts beneficial effects in pathophysiological conditions whereas reduced activity is usually associated with disease conditions. Here, we demonstrate that SIRT6 deacetylates H3K56ac in myofibers to suppress expression of utrophin, a dystrophin-related protein stabilizing the sarcolemma in absence of dystrophin. Inactivation of Sirt6 in dystrophin-deficient mdx mice reduced damage of myofibers, ameliorated dystrophic muscle pathology, and improved muscle function, leading to attenuated activation of muscle stem cells (MuSCs). ChIP-seq and locus-specific recruitment of SIRT6 using a CRISPR-dCas9/gRNA approach revealed that SIRT6 is critical for removal of H3K56ac at the Downstream utrophin Enhancer (DUE), which is indispensable for utrophin expression. We conclude that epigenetic manipulation of utrophin expression is a promising approach for the treatment of Duchenne Muscular Dystrophy (DMD). Utrophin is a dystrophin-related protein stabilizing the sarcolemma in absence of dystrophin. Here the authors report that inactivation of the protein deacetylase SIRT6, involved in the deacetylation of the epigenetic mark H3K56ac in muscle cells, increases expression of utrophin and ameliorates dystrophic muscle pathology in mice.
Collapse
Affiliation(s)
- Angelina M Georgieva
- Department of Cardiac Development and Remodeling, Max Planck Institute for Heart and Lung Research, 61231, Bad Nauheim, Germany
| | - Xinyue Guo
- Department of Cardiac Development and Remodeling, Max Planck Institute for Heart and Lung Research, 61231, Bad Nauheim, Germany
| | - Marek Bartkuhn
- Biomedical Informatics and Systems Medicine, Justus Liebig University, Giessen, Germany
| | - Stefan Günther
- Department of Cardiac Development and Remodeling, Max Planck Institute for Heart and Lung Research, 61231, Bad Nauheim, Germany
| | - Carsten Künne
- Department of Cardiac Development and Remodeling, Max Planck Institute for Heart and Lung Research, 61231, Bad Nauheim, Germany
| | - Christian Smolka
- Department of Cardiac Development and Remodeling, Max Planck Institute for Heart and Lung Research, 61231, Bad Nauheim, Germany
| | - Ann Atzberger
- Department of Cardiac Development and Remodeling, Max Planck Institute for Heart and Lung Research, 61231, Bad Nauheim, Germany
| | - Ulrich Gärtner
- Institute for Anatomy and Cell Biology, University of Giessen, Giessen, Germany
| | - Kamel Mamchaoui
- Sorbonne Université, Inserm, Institut de Myologie, Centre de Recherche en Myologie, F-75013, Paris, France
| | - Eva Bober
- Department of Cardiac Development and Remodeling, Max Planck Institute for Heart and Lung Research, 61231, Bad Nauheim, Germany
| | - Yonggang Zhou
- Department of Cardiac Development and Remodeling, Max Planck Institute for Heart and Lung Research, 61231, Bad Nauheim, Germany
| | - Xuejun Yuan
- Department of Cardiac Development and Remodeling, Max Planck Institute for Heart and Lung Research, 61231, Bad Nauheim, Germany.
| | - Thomas Braun
- Department of Cardiac Development and Remodeling, Max Planck Institute for Heart and Lung Research, 61231, Bad Nauheim, Germany.
| |
Collapse
|
2
|
Smolka C, Schlösser D, Koentges C, Tarkhnishvili A, Gorka O, Pfeifer D, Bemtgen X, Asmussen A, Groß O, Diehl P, Moser M, Bode C, Bugger H, Grundmann S, Pankratz F. Cardiomyocyte-specific miR-100 overexpression preserves heart function under pressure overload in mice and diminishes fatty acid uptake as well as ROS production by direct suppression of Nox4 and CD36. FASEB J 2021; 35:e21956. [PMID: 34605573 DOI: 10.1096/fj.202100829rr] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2021] [Revised: 09/08/2021] [Accepted: 09/13/2021] [Indexed: 12/16/2022]
Abstract
MicroRNAs are key regulators of the cardiac response to injury. MiR-100 has recently been suggested to be involved in different forms of heart failure, but functional studies are lacking. In the present study, we examined the impact of transgenic miR-100 overexpression on cardiac structure and function during physiological aging and pathological pressure-overload-induced heart failure in mice after transverse aortic constriction surgery. MiR-100 was moderately upregulated after induction of pressure overload in mice. While in our transgenic model the cardiomyocyte-specific overexpression of miR-100 did not result in an obvious cardiac phenotype in unchallenged mice, the transgenic mouse strain exhibited less left ventricular dilatation and a higher ejection fraction than wildtype animals, demonstrating an attenuation of maladaptive cardiac remodeling by miR-100. Cardiac transcriptome analysis identified a repression of several regulatory genes related to cardiac metabolism, lipid peroxidation, and production of reactive oxygen species (ROS) by miR-100 overexpression, possibly mediating the observed functional effects. While the modulation of ROS-production seemed to be indirectly affected by miR-100 via Alox5-and Nox4-downregulation, we demonstrated that miR-100 induced a direct repression of the scavenger protein CD36 in murine hearts resulting in a decreased uptake of long-chain fatty acids and an alteration of mitochondrial respiratory function with an enhanced glycolytic state. In summary, we identified miR-100 as a modulator of cardiac metabolism and ROS production without an apparent cardiac phenotype at baseline but a protective effect under conditions of pressure-overload-induced cardiac stress, providing new insight into the mechanisms of heart failure.
Collapse
Affiliation(s)
- Christian Smolka
- Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Delia Schlösser
- Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Christoph Koentges
- Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Aleksandre Tarkhnishvili
- Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Oliver Gorka
- Institute of Neuropathology, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Dietmar Pfeifer
- Department of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Xavier Bemtgen
- Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Alexander Asmussen
- Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Olaf Groß
- Institute of Neuropathology, Faculty of Medicine, University of Freiburg, Freiburg, Germany.,Signalling Research Centres BIOSS and CIBSS, University of Freiburg, Freiburg, Germany.,Center for Basics in NeuroModulation (NeuroModulBasics), Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Philipp Diehl
- Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Martin Moser
- Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Christoph Bode
- Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Heiko Bugger
- Division of Cardiology, Medical University of Graz, Graz, Austria
| | - Sebastian Grundmann
- Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Franziska Pankratz
- Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| |
Collapse
|
3
|
Gissler MC, Anto-Michel N, Pennig J, Scherrer P, Li X, Marchini T, Pfeiffer K, Härdtner C, Abogunloko T, Mwinyella T, Sol Mitre L, Spiga L, Koentges C, Smolka C, von Elverfeldt D, Hoppe N, Stachon P, Dufner B, Heidt T, Piepenburg S, Hilgendorf I, Bjune JI, Dankel SN, Mellgren G, Seifert G, Eisenhardt SU, Bugger H, von Zur Muhlen C, Bode C, Zirlik A, Wolf D, Willecke F. Genetic Deficiency of TRAF5 Promotes Adipose Tissue Inflammation and Aggravates Diet-Induced Obesity in Mice. Arterioscler Thromb Vasc Biol 2021; 41:2563-2574. [PMID: 34348490 DOI: 10.1161/atvbaha.121.316677] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Objective: The accumulation of inflammatory leukocytes is a prerequisite of adipose tissue inflammation during cardiometabolic disease. We previously reported that a genetic deficiency of the intracellular signaling adaptor TRAF5 (TNF [tumor necrosis factor] receptor-associated factor 5) accelerates atherosclerosis in mice by increasing inflammatory cell recruitment. Here, we tested the hypothesis that an impairment of TRAF5 signaling modulates adipose tissue inflammation and its metabolic complications in a model of diet-induced obesity in mice. Approach and Results: To induce diet-induced obesity and adipose tissue inflammation, wild-type or Traf5-/- mice consumed a high-fat diet for 18 weeks. Traf5-/- mice showed an increased weight gain, impaired insulin tolerance, and increased fasting blood glucose. Weight of livers and peripheral fat pads was increased in Traf5-/- mice, whereas lean tissue weight and growth were not affected. Flow cytometry of the stromal vascular fraction of visceral adipose tissue from Traf5-/- mice revealed an increase in cytotoxic T cells, CD11c+ macrophages, and increased gene expression of proinflammatory cytokines and chemokines. At the level of cell types, expression of TNF[alpha], MIP (macrophage inflammatory protein)-1[alpha], MCP (monocyte chemoattractant protein)-1, and RANTES (regulated on activation, normal T-cell expressed and secreted) was significantly upregulated in Traf5-deficient adipocytes but not in Traf5-deficient leukocytes from visceral adipose tissue. Finally, Traf5 expression was lower in adipocytes from obese patients and mice and recovered in adipose tissue of obese patients one year after bariatric surgery. Conclusions: We show that a genetic deficiency of TRAF5 in mice aggravates diet-induced obesity and its metabolic derangements by a proinflammatory response in adipocytes. Our data indicate that TRAF5 may promote anti-inflammatory and obesity-preventing signaling events in adipose tissue.
Collapse
Affiliation(s)
- Mark Colin Gissler
- Cardiology and Angiology I, University Heart Center, Faculty of Medicine, University of Freiburg, Germany (M.C.G., J.P., P.S., X.L., T. Marchini, K.P., C.H., T.A., T. Mwinyella, L.S.M., L.S., C.K., C.S., N.H., P.S., B.D., T.H., S.P., I.H., C.v.z.M., C.B., D.W., F.W.)
| | - Nathaly Anto-Michel
- Department of Cardiology, Medical University of Graz, Austria (N.A.M., H.B., A.Z.)
| | - Jan Pennig
- Cardiology and Angiology I, University Heart Center, Faculty of Medicine, University of Freiburg, Germany (M.C.G., J.P., P.S., X.L., T. Marchini, K.P., C.H., T.A., T. Mwinyella, L.S.M., L.S., C.K., C.S., N.H., P.S., B.D., T.H., S.P., I.H., C.v.z.M., C.B., D.W., F.W.)
| | - Philipp Scherrer
- Cardiology and Angiology I, University Heart Center, Faculty of Medicine, University of Freiburg, Germany (M.C.G., J.P., P.S., X.L., T. Marchini, K.P., C.H., T.A., T. Mwinyella, L.S.M., L.S., C.K., C.S., N.H., P.S., B.D., T.H., S.P., I.H., C.v.z.M., C.B., D.W., F.W.)
| | - Xiaowei Li
- Cardiology and Angiology I, University Heart Center, Faculty of Medicine, University of Freiburg, Germany (M.C.G., J.P., P.S., X.L., T. Marchini, K.P., C.H., T.A., T. Mwinyella, L.S.M., L.S., C.K., C.S., N.H., P.S., B.D., T.H., S.P., I.H., C.v.z.M., C.B., D.W., F.W.)
| | - Timoteo Marchini
- Cardiology and Angiology I, University Heart Center, Faculty of Medicine, University of Freiburg, Germany (M.C.G., J.P., P.S., X.L., T. Marchini, K.P., C.H., T.A., T. Mwinyella, L.S.M., L.S., C.K., C.S., N.H., P.S., B.D., T.H., S.P., I.H., C.v.z.M., C.B., D.W., F.W.)
| | - Katharina Pfeiffer
- Cardiology and Angiology I, University Heart Center, Faculty of Medicine, University of Freiburg, Germany (M.C.G., J.P., P.S., X.L., T. Marchini, K.P., C.H., T.A., T. Mwinyella, L.S.M., L.S., C.K., C.S., N.H., P.S., B.D., T.H., S.P., I.H., C.v.z.M., C.B., D.W., F.W.)
| | - Carmen Härdtner
- Cardiology and Angiology I, University Heart Center, Faculty of Medicine, University of Freiburg, Germany (M.C.G., J.P., P.S., X.L., T. Marchini, K.P., C.H., T.A., T. Mwinyella, L.S.M., L.S., C.K., C.S., N.H., P.S., B.D., T.H., S.P., I.H., C.v.z.M., C.B., D.W., F.W.)
| | - Tijani Abogunloko
- Cardiology and Angiology I, University Heart Center, Faculty of Medicine, University of Freiburg, Germany (M.C.G., J.P., P.S., X.L., T. Marchini, K.P., C.H., T.A., T. Mwinyella, L.S.M., L.S., C.K., C.S., N.H., P.S., B.D., T.H., S.P., I.H., C.v.z.M., C.B., D.W., F.W.)
| | - Timothy Mwinyella
- Cardiology and Angiology I, University Heart Center, Faculty of Medicine, University of Freiburg, Germany (M.C.G., J.P., P.S., X.L., T. Marchini, K.P., C.H., T.A., T. Mwinyella, L.S.M., L.S., C.K., C.S., N.H., P.S., B.D., T.H., S.P., I.H., C.v.z.M., C.B., D.W., F.W.)
| | - Lucia Sol Mitre
- Cardiology and Angiology I, University Heart Center, Faculty of Medicine, University of Freiburg, Germany (M.C.G., J.P., P.S., X.L., T. Marchini, K.P., C.H., T.A., T. Mwinyella, L.S.M., L.S., C.K., C.S., N.H., P.S., B.D., T.H., S.P., I.H., C.v.z.M., C.B., D.W., F.W.)
| | - Lisa Spiga
- Cardiology and Angiology I, University Heart Center, Faculty of Medicine, University of Freiburg, Germany (M.C.G., J.P., P.S., X.L., T. Marchini, K.P., C.H., T.A., T. Mwinyella, L.S.M., L.S., C.K., C.S., N.H., P.S., B.D., T.H., S.P., I.H., C.v.z.M., C.B., D.W., F.W.)
| | - Christoph Koentges
- Cardiology and Angiology I, University Heart Center, Faculty of Medicine, University of Freiburg, Germany (M.C.G., J.P., P.S., X.L., T. Marchini, K.P., C.H., T.A., T. Mwinyella, L.S.M., L.S., C.K., C.S., N.H., P.S., B.D., T.H., S.P., I.H., C.v.z.M., C.B., D.W., F.W.)
- Institute of Neuropathology (C.K.), Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Germany
| | - Christian Smolka
- Cardiology and Angiology I, University Heart Center, Faculty of Medicine, University of Freiburg, Germany (M.C.G., J.P., P.S., X.L., T. Marchini, K.P., C.H., T.A., T. Mwinyella, L.S.M., L.S., C.K., C.S., N.H., P.S., B.D., T.H., S.P., I.H., C.v.z.M., C.B., D.W., F.W.)
| | - Dominik von Elverfeldt
- Department of Radiology, Medical Physics (D.v.E.), Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Germany
| | - Natalie Hoppe
- Cardiology and Angiology I, University Heart Center, Faculty of Medicine, University of Freiburg, Germany (M.C.G., J.P., P.S., X.L., T. Marchini, K.P., C.H., T.A., T. Mwinyella, L.S.M., L.S., C.K., C.S., N.H., P.S., B.D., T.H., S.P., I.H., C.v.z.M., C.B., D.W., F.W.)
| | - Peter Stachon
- Cardiology and Angiology I, University Heart Center, Faculty of Medicine, University of Freiburg, Germany (M.C.G., J.P., P.S., X.L., T. Marchini, K.P., C.H., T.A., T. Mwinyella, L.S.M., L.S., C.K., C.S., N.H., P.S., B.D., T.H., S.P., I.H., C.v.z.M., C.B., D.W., F.W.)
| | - Bianca Dufner
- Cardiology and Angiology I, University Heart Center, Faculty of Medicine, University of Freiburg, Germany (M.C.G., J.P., P.S., X.L., T. Marchini, K.P., C.H., T.A., T. Mwinyella, L.S.M., L.S., C.K., C.S., N.H., P.S., B.D., T.H., S.P., I.H., C.v.z.M., C.B., D.W., F.W.)
| | - Timo Heidt
- Cardiology and Angiology I, University Heart Center, Faculty of Medicine, University of Freiburg, Germany (M.C.G., J.P., P.S., X.L., T. Marchini, K.P., C.H., T.A., T. Mwinyella, L.S.M., L.S., C.K., C.S., N.H., P.S., B.D., T.H., S.P., I.H., C.v.z.M., C.B., D.W., F.W.)
| | - Sven Piepenburg
- Cardiology and Angiology I, University Heart Center, Faculty of Medicine, University of Freiburg, Germany (M.C.G., J.P., P.S., X.L., T. Marchini, K.P., C.H., T.A., T. Mwinyella, L.S.M., L.S., C.K., C.S., N.H., P.S., B.D., T.H., S.P., I.H., C.v.z.M., C.B., D.W., F.W.)
| | - Ingo Hilgendorf
- Cardiology and Angiology I, University Heart Center, Faculty of Medicine, University of Freiburg, Germany (M.C.G., J.P., P.S., X.L., T. Marchini, K.P., C.H., T.A., T. Mwinyella, L.S.M., L.S., C.K., C.S., N.H., P.S., B.D., T.H., S.P., I.H., C.v.z.M., C.B., D.W., F.W.)
| | - Jan-Inge Bjune
- Center for Diabetes Research (J.-I.B., S.N.D., G.M.), University of Bergen, Norway
- Mohn Nutrition Research Laboratory, Department of Clinical Science (J.-I.B., S.N.D., G.M.), University of Bergen, Norway
- Hormone Laboratory, Department of Medical Biochemistry and Pharmacology, Haukeland University Hospital, Bergen, Norway (J.-I.B., S.N.D., G.M.)
| | - Simon N Dankel
- Center for Diabetes Research (J.-I.B., S.N.D., G.M.), University of Bergen, Norway
- Mohn Nutrition Research Laboratory, Department of Clinical Science (J.-I.B., S.N.D., G.M.), University of Bergen, Norway
- Hormone Laboratory, Department of Medical Biochemistry and Pharmacology, Haukeland University Hospital, Bergen, Norway (J.-I.B., S.N.D., G.M.)
| | - Gunnar Mellgren
- Center for Diabetes Research (J.-I.B., S.N.D., G.M.), University of Bergen, Norway
- Mohn Nutrition Research Laboratory, Department of Clinical Science (J.-I.B., S.N.D., G.M.), University of Bergen, Norway
- Hormone Laboratory, Department of Medical Biochemistry and Pharmacology, Haukeland University Hospital, Bergen, Norway (J.-I.B., S.N.D., G.M.)
| | - Gabriel Seifert
- Department of General and Visceral Surgery (G.S.), Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Germany
| | - Steffen U Eisenhardt
- Department of Plastic and Hand Surgery, Medical Center, University of Freiburg, Faculty of Medicine, University of Freiburg, Breisgau, Germany (S.U.E.)
| | - Heiko Bugger
- Department of Cardiology, Medical University of Graz, Austria (N.A.M., H.B., A.Z.)
| | - Constantin von Zur Muhlen
- Cardiology and Angiology I, University Heart Center, Faculty of Medicine, University of Freiburg, Germany (M.C.G., J.P., P.S., X.L., T. Marchini, K.P., C.H., T.A., T. Mwinyella, L.S.M., L.S., C.K., C.S., N.H., P.S., B.D., T.H., S.P., I.H., C.v.z.M., C.B., D.W., F.W.)
| | - Christoph Bode
- Cardiology and Angiology I, University Heart Center, Faculty of Medicine, University of Freiburg, Germany (M.C.G., J.P., P.S., X.L., T. Marchini, K.P., C.H., T.A., T. Mwinyella, L.S.M., L.S., C.K., C.S., N.H., P.S., B.D., T.H., S.P., I.H., C.v.z.M., C.B., D.W., F.W.)
| | - Andreas Zirlik
- Department of Cardiology, Medical University of Graz, Austria (N.A.M., H.B., A.Z.)
| | - Dennis Wolf
- Cardiology and Angiology I, University Heart Center, Faculty of Medicine, University of Freiburg, Germany (M.C.G., J.P., P.S., X.L., T. Marchini, K.P., C.H., T.A., T. Mwinyella, L.S.M., L.S., C.K., C.S., N.H., P.S., B.D., T.H., S.P., I.H., C.v.z.M., C.B., D.W., F.W.)
| | - Florian Willecke
- Cardiology and Angiology I, University Heart Center, Faculty of Medicine, University of Freiburg, Germany (M.C.G., J.P., P.S., X.L., T. Marchini, K.P., C.H., T.A., T. Mwinyella, L.S.M., L.S., C.K., C.S., N.H., P.S., B.D., T.H., S.P., I.H., C.v.z.M., C.B., D.W., F.W.)
- Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, Ruhr-Universität Bochum, Bad Oeynhausen, Germany (F.W.)
| |
Collapse
|
4
|
Smolka C, Schlösser D, Hohnloser C, Bemtgen X, Jänich C, Schneider L, Martin J, Pfeifer D, Moser M, Hasselblatt P, Bode C, Grundmann S, Pankratz F. MiR-100 overexpression attenuates high fat diet induced weight gain, liver steatosis, hypertriglyceridemia and development of metabolic syndrome in mice. Mol Med 2021; 27:101. [PMID: 34488621 PMCID: PMC8422764 DOI: 10.1186/s10020-021-00364-6] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2021] [Accepted: 08/25/2021] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND Diet-induced obesity can result in the development of a diverse spectrum of cardiovascular and metabolic diseases, including type 2 diabetes, dyslipidemia, non-alcoholic liver steatosis and atherosclerotic disease. MicroRNAs have been described to be important regulators of metabolism and disease development. METHODS In the current study, we investigated the effects of ubiquitous miR-100 overexpression on weight gain and the metabolic phenotype in a newly generated transgenic mouse strain under normal chow and high fat diet and used microarray expression analysis to identify new potential target genes of miR-100. RESULTS While transgenic overexpression of miR-100 did not significantly affect weight and metabolism under a normal diet, miR-100 overexpressing mice showed a reduced weight gain under a high fat diet compared to wildtype mice, despite an equal calorie intake. This was accompanied by less visceral and subcutaneous fat development and lover serum LDL cholesterol. In addition, transgenic miR-100 mice were more glucose tolerant and insulin sensitive and demonstrated increased energy expenditure under high fat diet feeding. A comprehensive gene expression profiling revealed the differential expression of several genes involved in lipid storage- and metabolism, among them CD36 and Cyp4A14. Our data showed a direct regulation of CD36 by miR-100, leading to a reduced fatty acid uptake in primary hepatocytes overexpressing miR-100 and the downregulation of several downstream mediators of lipid metabolism such as ACC1, FABP4, FAS and PPARγ in the liver. CONCLUSIONS Our findings demonstrate a protective role of miR-100 in high fat diet induced metabolic syndrome and liver steatosis, partially mediated by the direct repression of CD36 and attenuation of hepatic lipid storage, implicating miR-100 as a possible therapeutic target in liver steatosis.
Collapse
Affiliation(s)
- Christian Smolka
- Department of Cardiology and Angiology I, University Heart Center Freiburg - Bad Krozingen, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Delia Schlösser
- Department of Cardiology and Angiology I, University Heart Center Freiburg - Bad Krozingen, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Catherine Hohnloser
- Department of Cardiology and Angiology I, University Heart Center Freiburg - Bad Krozingen, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Xavier Bemtgen
- Department of Cardiology and Angiology I, University Heart Center Freiburg - Bad Krozingen, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Caterina Jänich
- Department of Cardiology and Angiology I, University Heart Center Freiburg - Bad Krozingen, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Laura Schneider
- Department of Cardiology and Angiology I, University Heart Center Freiburg - Bad Krozingen, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Julien Martin
- Department of Cardiology and Angiology I, University Heart Center Freiburg - Bad Krozingen, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Dietmar Pfeifer
- Department of Hematology, Oncology and Stem Cell Transplantation, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Martin Moser
- Department of Cardiology and Angiology I, University Heart Center Freiburg - Bad Krozingen, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Peter Hasselblatt
- Department of Medicine II, Gastroenterology, Hepatology, Endocrinology, and Infectious Diseases, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Christoph Bode
- Department of Cardiology and Angiology I, University Heart Center Freiburg - Bad Krozingen, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Sebastian Grundmann
- Department of Cardiology and Angiology I, University Heart Center Freiburg - Bad Krozingen, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Franziska Pankratz
- Department of Cardiology and Angiology I, University Heart Center Freiburg - Bad Krozingen, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
| |
Collapse
|
5
|
Asmussen A, Busch HJ, Helbing T, Bemtgen X, Smolka C, Bode C, Fink K, Grundmann S. Monocyte subset distribution and surface expression of HLA-DR and CD14 in patients after cardiopulmonary resuscitation. Sci Rep 2021; 11:12403. [PMID: 34117334 PMCID: PMC8196031 DOI: 10.1038/s41598-021-91948-z] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2021] [Accepted: 05/31/2021] [Indexed: 12/11/2022] Open
Abstract
Systemic inflammation is a major feature of the post-cardiac arrest syndrome. The three monocyte subpopulations are thought to play an important role in this inflammatory state because they are endowed with numerous pattern recognition receptors, such as CD14, that have been associated with ischemia-reperfusion injury. By contrast, an exaggerated antiinflammatory response has also been described following cardiac arrest, which may be mediated by downregulation of antigen presentation receptor HLA-DR. We report the composition of monocyte subpopulations and the expression of CD14 and HLA-DR following cardiac arrest. Blood specimens were collected from 32 patients at three timepoints in the first 48 h after cardiac arrest. Monocyte subset composition was determined by flow cytometry based on the expression of CD14, CD16, and HLA-DR. Monocyte subset composition and the expression of CD14 and HLA-DR were correlated with patient outcomes. The results were compared to 19 patients with coronary artery disease. Cardiac arrest patients showed a significant decline in the percentage of nonclassical monocytes. Monocyte CD14 expression was upregulated after 24 h and correlated with the time to return of spontaneous circulation. Downregulation of HLA-DR expression was observed mainly among classical monocytes and significantly correlated with the dose of norepinephrine used to treat shock. Downregulation of HLA-DR among nonclassical and intermediate monocytes was significantly associated with disease severity. Our data demonstrate the disturbance of monocyte subset composition with a significant decline in nonclassical monocytes at an early stage following cardiac arrest. Our findings suggest the simultaneous presence of hyperinflammation, as evidenced by upregulation of CD14, and monocyte deactivation, characterized by downregulation of HLA-DR. The extent of monocyte deactivation was significantly correlated with disease severity.
Collapse
Affiliation(s)
- Alexander Asmussen
- Department of Cardiology and Angiology I, University Heart Center Freiburg - Bad Krozingen, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg im Breisgau, Germany.
| | - Hans-Jörg Busch
- University Emergency Center, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Sir-Hans-A.-Krebs-Straße, 79106, Freiburg im Breisgau, Germany
| | - Thomas Helbing
- Department of Cardiology and Angiology I, University Heart Center Freiburg - Bad Krozingen, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg im Breisgau, Germany.,Department of Cardiology, Heart Center Oldenburg, University of Oldenburg, Rahel-Straus-Str. 10, 26133, Oldenburg, Germany
| | - Xavier Bemtgen
- Department of Cardiology and Angiology I, University Heart Center Freiburg - Bad Krozingen, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg im Breisgau, Germany
| | - Christian Smolka
- Department of Cardiology and Angiology I, University Heart Center Freiburg - Bad Krozingen, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg im Breisgau, Germany
| | - Christoph Bode
- Department of Cardiology and Angiology I, University Heart Center Freiburg - Bad Krozingen, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg im Breisgau, Germany
| | - Katrin Fink
- University Emergency Center, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Sir-Hans-A.-Krebs-Straße, 79106, Freiburg im Breisgau, Germany
| | - Sebastian Grundmann
- Department of Cardiology and Angiology I, University Heart Center Freiburg - Bad Krozingen, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg im Breisgau, Germany
| |
Collapse
|
6
|
De Filippo O, Gili S, Montefusco A, Esposito G, Cirillo P, Cortese B, Di Palma G, Mancone M, Tamburino C, Smolka C, Baumbach A, D'Ascenzo F. P5584Long term outcome of STENTYS self-apposing sirolimus eluting stent in the real life: a multicenter experience. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.p5584] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- O De Filippo
- Hospital Molinette of the University Hospital S. Giovanni Battista/City University Hosp of Health an, Turin, Italy
| | - S Gili
- Hospital Molinette of the University Hospital S. Giovanni Battista/City University Hosp of Health an, Turin, Italy
| | - A Montefusco
- Hospital Molinette of the University Hospital S. Giovanni Battista/City University Hosp of Health an, Turin, Italy
| | - G Esposito
- AOU Policlinico “Federico II”, Advanced Biomedical Sciences, Napoli, Italy
| | - P Cirillo
- AOU Policlinico “Federico II”, Advanced Biomedical Sciences, Napoli, Italy
| | - B Cortese
- Fatebenefratelli Hospital, Milan, Italy
| | | | - M Mancone
- Sapienza University of Rome, Rome, Italy
| | | | - C Smolka
- Medical University of Silesia, Katowice, Poland
| | - A Baumbach
- Queen Mary University of London, London, United Kingdom
| | - F D'Ascenzo
- Hospital Molinette of the University Hospital S. Giovanni Battista/City University Hosp of Health an, Turin, Italy
| |
Collapse
|
7
|
Pankratz F, Hohnloser C, Bemtgen X, Jaenich C, Kreuzaler S, Hoefer I, Pasterkamp G, Mastroianni J, Zeiser R, Smolka C, Schneider L, Martin J, Juschkat M, Helbing T, Moser M, Bode C, Grundmann S. MicroRNA-100 Suppresses Chronic Vascular Inflammation by Stimulation of Endothelial Autophagy. Circ Res 2017; 122:417-432. [PMID: 29208678 DOI: 10.1161/circresaha.117.311428] [Citation(s) in RCA: 82] [Impact Index Per Article: 11.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/22/2017] [Revised: 11/13/2017] [Accepted: 12/01/2017] [Indexed: 12/31/2022]
Abstract
RATIONALE The interaction of circulating cells within the vascular wall is a critical event in chronic inflammatory processes, such as atherosclerosis, but the control of the vascular inflammatory state is still largely unclear. OBJECTIVE This study was undertaken to characterize the function of the endothelial-enriched microRNA miR-100 during vascular inflammation and atherogenesis. METHODS AND RESULTS Based on a transcriptome analysis of endothelial cells after miR-100 overexpression, we identified miR-100 as a potent suppressor of endothelial adhesion molecule expression, resulting in attenuated leukocyte-endothelial interaction in vitro and in vivo as shown by flow cytometry and intravital imaging. Mechanistically, miR-100 directly repressed several components of mammalian target of rapamycin complex 1-signaling, including mammalian target of rapamycin and raptor, which resulted in a stimulation of endothelial autophagy and attenuated nuclear factor κB signaling in vitro and in vivo. In a low-density lipoprotein receptor-deficient atherosclerotic mouse model, pharmacological inhibition of miR-100 resulted in enhanced plaque lesion formation and a higher macrophage content of the plaque, whereas a systemic miR-100 replacement therapy had protective effects and attenuated atherogenesis, resulting in a decrease of plaque area by 45%. Finally, analysis of miR-100 expression in >70 samples obtained during carotid endarterectomy revealed that local miR-100 expression was inversely correlated with inflammatory cell content in patients. CONCLUSIONS In summary, we describe an anti-inflammatory function of miR-100 in the vascular response to injury and inflammation and identify an important novel modulator of mammalian target of rapamycin signaling and autophagy in the vascular system. Our findings of miR-100 as a potential protective anti-athero-miR suggest that the therapeutic replacement of this microRNA could be a potential strategy for the treatment of chronic inflammatory diseases, such as atherosclerosis, in the future.
Collapse
Affiliation(s)
- Franziska Pankratz
- From the Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Germany (F.P., C.H., X.B., C.J., S.K., C.S., L.S., J.M., M.J., T.H., M.M., C.B., S.G.); Laboratory of Clinical Chemistry and Haematology, University Medical Center Utrecht, The Netherlands (I.H., G.P.); and Department of Hematology, Oncology, and Stem Cell Transplantation, Medical Center, Faculty of Medicine, University of Freiburg, Germany (J.M., R.Z.)
| | - Catherine Hohnloser
- From the Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Germany (F.P., C.H., X.B., C.J., S.K., C.S., L.S., J.M., M.J., T.H., M.M., C.B., S.G.); Laboratory of Clinical Chemistry and Haematology, University Medical Center Utrecht, The Netherlands (I.H., G.P.); and Department of Hematology, Oncology, and Stem Cell Transplantation, Medical Center, Faculty of Medicine, University of Freiburg, Germany (J.M., R.Z.)
| | - Xavier Bemtgen
- From the Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Germany (F.P., C.H., X.B., C.J., S.K., C.S., L.S., J.M., M.J., T.H., M.M., C.B., S.G.); Laboratory of Clinical Chemistry and Haematology, University Medical Center Utrecht, The Netherlands (I.H., G.P.); and Department of Hematology, Oncology, and Stem Cell Transplantation, Medical Center, Faculty of Medicine, University of Freiburg, Germany (J.M., R.Z.)
| | - Caterina Jaenich
- From the Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Germany (F.P., C.H., X.B., C.J., S.K., C.S., L.S., J.M., M.J., T.H., M.M., C.B., S.G.); Laboratory of Clinical Chemistry and Haematology, University Medical Center Utrecht, The Netherlands (I.H., G.P.); and Department of Hematology, Oncology, and Stem Cell Transplantation, Medical Center, Faculty of Medicine, University of Freiburg, Germany (J.M., R.Z.)
| | - Sheena Kreuzaler
- From the Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Germany (F.P., C.H., X.B., C.J., S.K., C.S., L.S., J.M., M.J., T.H., M.M., C.B., S.G.); Laboratory of Clinical Chemistry and Haematology, University Medical Center Utrecht, The Netherlands (I.H., G.P.); and Department of Hematology, Oncology, and Stem Cell Transplantation, Medical Center, Faculty of Medicine, University of Freiburg, Germany (J.M., R.Z.)
| | - Imo Hoefer
- From the Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Germany (F.P., C.H., X.B., C.J., S.K., C.S., L.S., J.M., M.J., T.H., M.M., C.B., S.G.); Laboratory of Clinical Chemistry and Haematology, University Medical Center Utrecht, The Netherlands (I.H., G.P.); and Department of Hematology, Oncology, and Stem Cell Transplantation, Medical Center, Faculty of Medicine, University of Freiburg, Germany (J.M., R.Z.)
| | - Gerard Pasterkamp
- From the Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Germany (F.P., C.H., X.B., C.J., S.K., C.S., L.S., J.M., M.J., T.H., M.M., C.B., S.G.); Laboratory of Clinical Chemistry and Haematology, University Medical Center Utrecht, The Netherlands (I.H., G.P.); and Department of Hematology, Oncology, and Stem Cell Transplantation, Medical Center, Faculty of Medicine, University of Freiburg, Germany (J.M., R.Z.)
| | - Justin Mastroianni
- From the Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Germany (F.P., C.H., X.B., C.J., S.K., C.S., L.S., J.M., M.J., T.H., M.M., C.B., S.G.); Laboratory of Clinical Chemistry and Haematology, University Medical Center Utrecht, The Netherlands (I.H., G.P.); and Department of Hematology, Oncology, and Stem Cell Transplantation, Medical Center, Faculty of Medicine, University of Freiburg, Germany (J.M., R.Z.)
| | - Robert Zeiser
- From the Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Germany (F.P., C.H., X.B., C.J., S.K., C.S., L.S., J.M., M.J., T.H., M.M., C.B., S.G.); Laboratory of Clinical Chemistry and Haematology, University Medical Center Utrecht, The Netherlands (I.H., G.P.); and Department of Hematology, Oncology, and Stem Cell Transplantation, Medical Center, Faculty of Medicine, University of Freiburg, Germany (J.M., R.Z.)
| | - Christian Smolka
- From the Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Germany (F.P., C.H., X.B., C.J., S.K., C.S., L.S., J.M., M.J., T.H., M.M., C.B., S.G.); Laboratory of Clinical Chemistry and Haematology, University Medical Center Utrecht, The Netherlands (I.H., G.P.); and Department of Hematology, Oncology, and Stem Cell Transplantation, Medical Center, Faculty of Medicine, University of Freiburg, Germany (J.M., R.Z.)
| | - Laura Schneider
- From the Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Germany (F.P., C.H., X.B., C.J., S.K., C.S., L.S., J.M., M.J., T.H., M.M., C.B., S.G.); Laboratory of Clinical Chemistry and Haematology, University Medical Center Utrecht, The Netherlands (I.H., G.P.); and Department of Hematology, Oncology, and Stem Cell Transplantation, Medical Center, Faculty of Medicine, University of Freiburg, Germany (J.M., R.Z.)
| | - Julien Martin
- From the Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Germany (F.P., C.H., X.B., C.J., S.K., C.S., L.S., J.M., M.J., T.H., M.M., C.B., S.G.); Laboratory of Clinical Chemistry and Haematology, University Medical Center Utrecht, The Netherlands (I.H., G.P.); and Department of Hematology, Oncology, and Stem Cell Transplantation, Medical Center, Faculty of Medicine, University of Freiburg, Germany (J.M., R.Z.)
| | - Maike Juschkat
- From the Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Germany (F.P., C.H., X.B., C.J., S.K., C.S., L.S., J.M., M.J., T.H., M.M., C.B., S.G.); Laboratory of Clinical Chemistry and Haematology, University Medical Center Utrecht, The Netherlands (I.H., G.P.); and Department of Hematology, Oncology, and Stem Cell Transplantation, Medical Center, Faculty of Medicine, University of Freiburg, Germany (J.M., R.Z.)
| | - Thomas Helbing
- From the Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Germany (F.P., C.H., X.B., C.J., S.K., C.S., L.S., J.M., M.J., T.H., M.M., C.B., S.G.); Laboratory of Clinical Chemistry and Haematology, University Medical Center Utrecht, The Netherlands (I.H., G.P.); and Department of Hematology, Oncology, and Stem Cell Transplantation, Medical Center, Faculty of Medicine, University of Freiburg, Germany (J.M., R.Z.)
| | - Martin Moser
- From the Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Germany (F.P., C.H., X.B., C.J., S.K., C.S., L.S., J.M., M.J., T.H., M.M., C.B., S.G.); Laboratory of Clinical Chemistry and Haematology, University Medical Center Utrecht, The Netherlands (I.H., G.P.); and Department of Hematology, Oncology, and Stem Cell Transplantation, Medical Center, Faculty of Medicine, University of Freiburg, Germany (J.M., R.Z.)
| | - Christoph Bode
- From the Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Germany (F.P., C.H., X.B., C.J., S.K., C.S., L.S., J.M., M.J., T.H., M.M., C.B., S.G.); Laboratory of Clinical Chemistry and Haematology, University Medical Center Utrecht, The Netherlands (I.H., G.P.); and Department of Hematology, Oncology, and Stem Cell Transplantation, Medical Center, Faculty of Medicine, University of Freiburg, Germany (J.M., R.Z.)
| | - Sebastian Grundmann
- From the Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Germany (F.P., C.H., X.B., C.J., S.K., C.S., L.S., J.M., M.J., T.H., M.M., C.B., S.G.); Laboratory of Clinical Chemistry and Haematology, University Medical Center Utrecht, The Netherlands (I.H., G.P.); and Department of Hematology, Oncology, and Stem Cell Transplantation, Medical Center, Faculty of Medicine, University of Freiburg, Germany (J.M., R.Z.).
| |
Collapse
|
8
|
Pankratz F, Bemtgen X, Zeiser R, Leonhardt F, Kreuzaler S, Hilgendorf I, Smolka C, Helbing T, Hoefer I, Esser JS, Kustermann M, Moser M, Bode C, Grundmann S. Response to Letter Regarding Article, "MicroRNA-155 Exerts Cell-Specific Antiangiogenic but Proarteriogenic Effects During Adaptive Neovascularization". Circulation 2016; 132:e376. [PMID: 26644256 DOI: 10.1161/circulationaha.115.018754] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Franziska Pankratz
- Department of Cardiology and Angiology I, Heart Center, University of Freiburg, Freiburg, Germany, Department of Biology, Albert-Ludwigs-University, Freiburg, Germany
| | - Xavier Bemtgen
- Department of Cardiology and Angiology I, Heart Center, University of Freiburg, Freiburg, Germany
| | - Robert Zeiser
- Department of Hematology and Oncology, University Hospital Freiburg, Freiburg, Germany
| | - Franziska Leonhardt
- Department of Biology, Albert-Ludwigs-University, Freiburg, Germany, Department of Hematology and Oncology, University Hospital Freiburg, Freiburg, Germany
| | - Sheena Kreuzaler
- Department of Cardiology and Angiology I, Heart Center, University of Freiburg, Freiburg, Germany
| | - Ingo Hilgendorf
- Department of Cardiology and Angiology I, Heart Center, University of Freiburg, Freiburg, Germany
| | - Christian Smolka
- Department of Cardiology and Angiology I, Heart Center, University of Freiburg, Freiburg, Germany
| | - Thomas Helbing
- Department of Cardiology and Angiology I, Heart Center, University of Freiburg, Freiburg, Germany
| | - Imo Hoefer
- Experimental Cardiology Laboratory, University Medical Center, Utrecht, the Netherlands
| | - Jennifer S Esser
- Department of Cardiology and Angiology I, Heart Center, University of Freiburg, Freiburg, Germany
| | - Max Kustermann
- Department of Cardiology and Angiology I, Heart Center, University of Freiburg, Freiburg, Germany
| | - Martin Moser
- Department of Cardiology and Angiology I, Heart Center, University of Freiburg, Freiburg, Germany
| | - Christoph Bode
- Department of Cardiology and Angiology I, Heart Center, University of Freiburg, Freiburg, Germany
| | - Sebastian Grundmann
- Department of Cardiology and Angiology I, Heart Center, University of Freiburg, Freiburg, Germany
| |
Collapse
|
9
|
Pankratz F, Bemtgen X, Zeiser R, Leonhardt F, Kreuzaler S, Hilgendorf I, Smolka C, Helbing T, Hoefer I, Esser JS, Kustermann M, Moser M, Bode C, Grundmann S. MicroRNA-155 Exerts Cell-Specific Antiangiogenic but Proarteriogenic Effects During Adaptive Neovascularization. Circulation 2015; 131:1575-89. [PMID: 25850724 DOI: 10.1161/circulationaha.114.014579] [Citation(s) in RCA: 67] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/03/2014] [Accepted: 03/03/2015] [Indexed: 11/16/2022]
Abstract
BACKGROUND Adaptive neovascularization after arterial occlusion is an important compensatory mechanism in cardiovascular disease and includes both the remodeling of pre-existing vessels to collateral arteries (arteriogenesis) and angiogenic capillary growth. We now aimed to identify regulatory microRNAs involved in the modulation of neovascularization after femoral artery occlusion in mice. METHODS AND RESULTS Using microRNA-transcriptome analysis, we identified miR-155 as a downregulated microRNA during hindlimb ischemia. Correspondingly, inhibition of miR-155 in endothelial cells had a stimulatory effect on proliferation and angiogenic tube formation via derepression of its direct target gene angiotensin II type 1 receptor. Surprisingly, miR-155-deficient mice showed an unexpected phenotype in vivo, with a strong reduction of blood flow recovery after femoral artery ligation (arteriogenesis) dependent on the attenuation of leukocyte-endothelial interaction and a reduction of proarteriogenic cytokine expression. Consistently, miR-155-deficient macrophages exhibit a specific alteration of the proarteriogenic cytokine expression profile, which is partly mediated by the direct miR-155 target gene SOCS-1. CONCLUSIONS Our data demonstrate that miR-155 exerts an antiangiogenic but proarteriogenic function in the regulation of neovascularization via the suppression of divergent cell-specific target genes and that its expression in both endothelial and bone marrow-derived cells is essential for arteriogenesis in response to hindlimb ischemia in mice.
Collapse
Affiliation(s)
- Franziska Pankratz
- From Department of Cardiology and Angiology I, Heart Center, University of Freiburg, Germany (F.P., X.B., S.K., I.Hi., C.S., T.H., J.S.E., M.K., M.M., C.B., S.G.); Department of Biology, Albert-Ludwigs-University, Freiburg, Germany (F.P., F.L.); Department of Hematology and Oncology, University Hospital Freiburg, Germany (R.Z., F.L.); and Experimental Cardiology Laboratory, University Medical Center Utrecht, The Netherlands (I.Ho.)
| | - Xavier Bemtgen
- From Department of Cardiology and Angiology I, Heart Center, University of Freiburg, Germany (F.P., X.B., S.K., I.Hi., C.S., T.H., J.S.E., M.K., M.M., C.B., S.G.); Department of Biology, Albert-Ludwigs-University, Freiburg, Germany (F.P., F.L.); Department of Hematology and Oncology, University Hospital Freiburg, Germany (R.Z., F.L.); and Experimental Cardiology Laboratory, University Medical Center Utrecht, The Netherlands (I.Ho.)
| | - Robert Zeiser
- From Department of Cardiology and Angiology I, Heart Center, University of Freiburg, Germany (F.P., X.B., S.K., I.Hi., C.S., T.H., J.S.E., M.K., M.M., C.B., S.G.); Department of Biology, Albert-Ludwigs-University, Freiburg, Germany (F.P., F.L.); Department of Hematology and Oncology, University Hospital Freiburg, Germany (R.Z., F.L.); and Experimental Cardiology Laboratory, University Medical Center Utrecht, The Netherlands (I.Ho.)
| | - Franziska Leonhardt
- From Department of Cardiology and Angiology I, Heart Center, University of Freiburg, Germany (F.P., X.B., S.K., I.Hi., C.S., T.H., J.S.E., M.K., M.M., C.B., S.G.); Department of Biology, Albert-Ludwigs-University, Freiburg, Germany (F.P., F.L.); Department of Hematology and Oncology, University Hospital Freiburg, Germany (R.Z., F.L.); and Experimental Cardiology Laboratory, University Medical Center Utrecht, The Netherlands (I.Ho.)
| | - Sheena Kreuzaler
- From Department of Cardiology and Angiology I, Heart Center, University of Freiburg, Germany (F.P., X.B., S.K., I.Hi., C.S., T.H., J.S.E., M.K., M.M., C.B., S.G.); Department of Biology, Albert-Ludwigs-University, Freiburg, Germany (F.P., F.L.); Department of Hematology and Oncology, University Hospital Freiburg, Germany (R.Z., F.L.); and Experimental Cardiology Laboratory, University Medical Center Utrecht, The Netherlands (I.Ho.)
| | - Ingo Hilgendorf
- From Department of Cardiology and Angiology I, Heart Center, University of Freiburg, Germany (F.P., X.B., S.K., I.Hi., C.S., T.H., J.S.E., M.K., M.M., C.B., S.G.); Department of Biology, Albert-Ludwigs-University, Freiburg, Germany (F.P., F.L.); Department of Hematology and Oncology, University Hospital Freiburg, Germany (R.Z., F.L.); and Experimental Cardiology Laboratory, University Medical Center Utrecht, The Netherlands (I.Ho.)
| | - Christian Smolka
- From Department of Cardiology and Angiology I, Heart Center, University of Freiburg, Germany (F.P., X.B., S.K., I.Hi., C.S., T.H., J.S.E., M.K., M.M., C.B., S.G.); Department of Biology, Albert-Ludwigs-University, Freiburg, Germany (F.P., F.L.); Department of Hematology and Oncology, University Hospital Freiburg, Germany (R.Z., F.L.); and Experimental Cardiology Laboratory, University Medical Center Utrecht, The Netherlands (I.Ho.)
| | - Thomas Helbing
- From Department of Cardiology and Angiology I, Heart Center, University of Freiburg, Germany (F.P., X.B., S.K., I.Hi., C.S., T.H., J.S.E., M.K., M.M., C.B., S.G.); Department of Biology, Albert-Ludwigs-University, Freiburg, Germany (F.P., F.L.); Department of Hematology and Oncology, University Hospital Freiburg, Germany (R.Z., F.L.); and Experimental Cardiology Laboratory, University Medical Center Utrecht, The Netherlands (I.Ho.)
| | - Imo Hoefer
- From Department of Cardiology and Angiology I, Heart Center, University of Freiburg, Germany (F.P., X.B., S.K., I.Hi., C.S., T.H., J.S.E., M.K., M.M., C.B., S.G.); Department of Biology, Albert-Ludwigs-University, Freiburg, Germany (F.P., F.L.); Department of Hematology and Oncology, University Hospital Freiburg, Germany (R.Z., F.L.); and Experimental Cardiology Laboratory, University Medical Center Utrecht, The Netherlands (I.Ho.)
| | - Jennifer S Esser
- From Department of Cardiology and Angiology I, Heart Center, University of Freiburg, Germany (F.P., X.B., S.K., I.Hi., C.S., T.H., J.S.E., M.K., M.M., C.B., S.G.); Department of Biology, Albert-Ludwigs-University, Freiburg, Germany (F.P., F.L.); Department of Hematology and Oncology, University Hospital Freiburg, Germany (R.Z., F.L.); and Experimental Cardiology Laboratory, University Medical Center Utrecht, The Netherlands (I.Ho.)
| | - Max Kustermann
- From Department of Cardiology and Angiology I, Heart Center, University of Freiburg, Germany (F.P., X.B., S.K., I.Hi., C.S., T.H., J.S.E., M.K., M.M., C.B., S.G.); Department of Biology, Albert-Ludwigs-University, Freiburg, Germany (F.P., F.L.); Department of Hematology and Oncology, University Hospital Freiburg, Germany (R.Z., F.L.); and Experimental Cardiology Laboratory, University Medical Center Utrecht, The Netherlands (I.Ho.)
| | - Martin Moser
- From Department of Cardiology and Angiology I, Heart Center, University of Freiburg, Germany (F.P., X.B., S.K., I.Hi., C.S., T.H., J.S.E., M.K., M.M., C.B., S.G.); Department of Biology, Albert-Ludwigs-University, Freiburg, Germany (F.P., F.L.); Department of Hematology and Oncology, University Hospital Freiburg, Germany (R.Z., F.L.); and Experimental Cardiology Laboratory, University Medical Center Utrecht, The Netherlands (I.Ho.)
| | - Christoph Bode
- From Department of Cardiology and Angiology I, Heart Center, University of Freiburg, Germany (F.P., X.B., S.K., I.Hi., C.S., T.H., J.S.E., M.K., M.M., C.B., S.G.); Department of Biology, Albert-Ludwigs-University, Freiburg, Germany (F.P., F.L.); Department of Hematology and Oncology, University Hospital Freiburg, Germany (R.Z., F.L.); and Experimental Cardiology Laboratory, University Medical Center Utrecht, The Netherlands (I.Ho.)
| | - Sebastian Grundmann
- From Department of Cardiology and Angiology I, Heart Center, University of Freiburg, Germany (F.P., X.B., S.K., I.Hi., C.S., T.H., J.S.E., M.K., M.M., C.B., S.G.); Department of Biology, Albert-Ludwigs-University, Freiburg, Germany (F.P., F.L.); Department of Hematology and Oncology, University Hospital Freiburg, Germany (R.Z., F.L.); and Experimental Cardiology Laboratory, University Medical Center Utrecht, The Netherlands (I.Ho.).
| |
Collapse
|
10
|
Jedrusik-Bode M, Studencka M, Smolka C, Baumann T, Schmidt H, Kampf J, Paap F, Martin S, Tazi J, Müller KM, Krüger M, Braun T, Bober E. The sirtuin SIRT6 regulates stress granule formation in C. elegans and mammals. J Cell Sci 2013; 126:5166-77. [PMID: 24013546 DOI: 10.1242/jcs.130708] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
SIRT6 is a NAD(+)-dependent deacetylase that modulates chromatin structure and safeguards genomic stability. Until now, SIRT6 has been assigned to the nucleus and only nuclear targets of SIRT6 are known. Here, we demonstrate that in response to stress, C. elegans SIR-2.4 and its mammalian orthologue SIRT6 localize to cytoplasmic stress granules, interact with various stress granule components and induce their assembly. Loss of SIRT6 or inhibition of its catalytic activity in mouse embryonic fibroblasts impairs stress granule formation and delays disassembly during recovery, whereas deficiency of SIR-2.4 diminishes maintenance of P granules and decreases survival of C. elegans under stress conditions. Our findings uncover a novel, evolutionary conserved function of SIRT6 in the maintenance of stress granules in response to stress.
Collapse
Affiliation(s)
- Monika Jedrusik-Bode
- Max Planck Institute for Biophysical Chemistry, Epigenetics in C. elegans group, Am Faßberg 11, 37077 Göttingen, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
|
12
|
Vakhrusheva O, Smolka C, Gajawada P, Kostin S, Boettger T, Kubin T, Braun T, Bober E. Sirt7 Increases Stress Resistance of Cardiomyocytes and Prevents Apoptosis and Inflammatory Cardiomyopathy in Mice. Circ Res 2008; 102:703-10. [DOI: 10.1161/circresaha.107.164558] [Citation(s) in RCA: 474] [Impact Index Per Article: 29.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Abstract
Sirt7 is a member of the mammalian sirtuin family consisting of 7 genes, Sirt1 to Sirt7, which all share a homology to the founding family member, the yeast Sir2 gene. Most sirtuins are supposed to act as histone/protein deacetylases, which use oxidized NAD in a sirtuin-specific, 2-step deacetylation reaction. To begin to decipher the biological role of Sirt7, we inactivated the Sirt7 gene in mice. Sirt7-deficient animals undergo a reduction in mean and maximum lifespans and develop heart hypertrophy and inflammatory cardiomyopathy. Sirt7 mutant hearts are also characterized by an extensive fibrosis, which leads to a 3-fold increase in collagen III accumulation. We found that Sirt7 interacts with p53 and efficiently deacetylates p53 in vitro, which corresponds to hyperacetylation of p53 in vivo and an increased rate of apoptosis in the myocardium of mutant mice. Sirt7-deficient primary cardiomyocytes show a ≈200% increase in basal apoptosis and a significantly diminished resistance to oxidative and genotoxic stress suggesting a critical role of Sirt7 in the regulation of stress responses and cell death in the heart. We propose that enhanced activation of p53 by lack of Sirt7-mediated deacetylation contributes to the heart phenotype of Sirt7 mutant mice.
Collapse
Affiliation(s)
- Olesya Vakhrusheva
- From the Max-Planck-Institute for Heart and Lung Research, Department of Cardiac Development and Remodelling, Bad Nauheim, Germany
| | - Christian Smolka
- From the Max-Planck-Institute for Heart and Lung Research, Department of Cardiac Development and Remodelling, Bad Nauheim, Germany
| | - Praveen Gajawada
- From the Max-Planck-Institute for Heart and Lung Research, Department of Cardiac Development and Remodelling, Bad Nauheim, Germany
| | - Sawa Kostin
- From the Max-Planck-Institute for Heart and Lung Research, Department of Cardiac Development and Remodelling, Bad Nauheim, Germany
| | - Thomas Boettger
- From the Max-Planck-Institute for Heart and Lung Research, Department of Cardiac Development and Remodelling, Bad Nauheim, Germany
| | - Thomas Kubin
- From the Max-Planck-Institute for Heart and Lung Research, Department of Cardiac Development and Remodelling, Bad Nauheim, Germany
| | - Thomas Braun
- From the Max-Planck-Institute for Heart and Lung Research, Department of Cardiac Development and Remodelling, Bad Nauheim, Germany
| | - Eva Bober
- From the Max-Planck-Institute for Heart and Lung Research, Department of Cardiac Development and Remodelling, Bad Nauheim, Germany
| |
Collapse
|